openPR Logo
Press release

Atopic Dermatitis Market Size to 2026: Velite Pharmaceuticals, Galderma SA, Pfizer Inc, Fujisawa Healthcare, Inc., Dow, Regeneron Pharmaceuticals, Inc

09-28-2020 08:53 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

Atopic Dermatitis Market

Atopic Dermatitis Market

The Atopic Dermatitis Market analysis report is a competent and deep analysis of the present situation and challenges. It also makes available analysis of market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2026. The market research document offers a comprehensive overview of the Atopic Dermatitis Market and contains thoughtful insights, facts, historical information, and statistically supported and industry-verified market data. This report focuses on the key drivers, restraints, market opportunities, threats and risks for market major players. Atopic Dermatitis Market report also encompasses forecasts using a suitable set of predictions and distinct research methodologies.

Few of the major competitors currently working in the atopic dermatitis  market are Velite Pharmaceuticals, Galderma SA, Pfizer Inc, Fujisawa Healthcare, Inc., Dow, Regeneron Pharmaceuticals, Inc, LEO Pharma A/S, Sanofi, Novartis AG, Bristol-Myers Squibb Company, Bayer AG, Meda Pharmaceuticals Inc., Connetics Corporation, ALLERGAN, and Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Encore Dermatology, Inc., AbbVie Inc. and few among others.

Global Atopic Dermatitis Market in the forecast period of 2019-2026. Growing number of atopic dermatitis population and robust product pipeline are the key drivers for market growth.

Get Sample Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-atopic-dermatitis-market

Key Developments in the Market:

In March 2017, Regeneron Pharmaceuticals, Inc. in a collaboration with Sanofi received the US FDA approval for Dupixent (dupilumab) injection for the treatment of moderate to severe atopic dermatitis (AD) in adult patient
In December 2016, Pfizer Inc. received the US FDA approval for Eucrisatm (crisaborole), a phosphodieterase-4 (PDE-4) inhibitor for the treatment of mild to moderate atopic dermatitis (AD) in padiatric patient as well as adult patient

Global Atopic Dermatitis Market By Mechanism of Action Type (Antihistamines, Topical corticosteroids, Emollients, Phosphodieterase-4 (PDE-4) inhibitor, Topical antiseptic and Others),  Mode of Administration (Injectable, Topical, Oral), Drug Type (Triamcinolone, Clobetasol, Tacrolimus topical, Betamethasone, Pimecrolimus, Fluocinonide, Hydrocortisone, Prednisone, Crisaborole, Fluticasone, Methylprednisolone  and Others), Distribution Channel (Mail Order Pharmacies, Hospital Pharmacies, Online Pharmacies, Drug Stores, Retail Pharmacies, Dermatology Clinics), Type (Hormone, Erythropoietin, Monoclonal Antibodies, and Calcitonin), Application (Cancer, Blood Disorders, and Chronic Diseases), End User (Hospitals, Research Centers, Clinics, Home Care), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Forecast to 2026

Market Definition: Global Atopic Dermatitis Market

Atopic dermatitis can be defined as a chronic inflammatory skin condition that affects patients of all age group and is a result of a complex interplay of multiple factors including environmental, immunological, genetic, and pharmacologic factors.

According to the article published in National Center for Biotechnology Information 2018, It was estimated that totoal population of atopic dermatitis in the United States over 4.9% ,  in Canada 4.4% and 3.5% in Europe. The prevalent was higher in female as comapared to male. Increasing number of atopic dermatitis cases worldwide and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Market Drivers

Strong product pipeline for atopic dermatitis
Availability of novel drug therapies and generic alternatives
Increase in awareness of atopic dermatitis
Growing cases of atopic dermatitis worldwide

Market Restraints

Upcoming patent expiry of products of many companies
Allergic reactions of off-label therapies
Effective treatment is either unavailable or unaffordable

Segmentation: Global Atopic Dermatitis Market

By Mechanism of Action Type

Antihistamines
Topical corticosteroids
Emollients
Phosphodieterase-4 (PDE-4) inhibitor
Topical antiseptic
Others

By Mode of Administration

Injectable
Topical
Oral

By Drug Type

Triamcinolone
Clobetasol
Tacrolimus topical
Betamethasone
Pimecrolimus
Fluocinonide
Hydrocortisone
Prednisone
Crisaborole
Fluticasone
Methylprednisolone
Others

By End- User

Hospitals
Research Centers
Clinics
Home Care

By Distribution Channel

Mail Order Pharmacies
Hospital Pharmacies
Online Pharmacies
Drug Stores
Retail Pharmacies
Dermatology Clinics

By Geography

North America
US.
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Thailand
Malaysia
Indonesia
Philippines
Rest of Asia Pacific
Middle East & Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of Middle East & Africa

For More Details In-Depth Inquiry @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-atopic-dermatitis-market

Competitive Analysis: Global Atopic Dermatitis Market

Global atopic dermatitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of atopic dermatitis market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Current and future of global atopic dermatitis market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Table of Contents:

Introduction
Market Segmentation
Market Overview
Executive Summary
Premium Insights
Global, By Component
Product Type
Delivery
Industry Type
Geography

10.1.    Overview

10.2.    North America

10.3.    Europe

10.4.    Asia-Pacific

10.5.    South America

10.6.    Middle East & Africa

Company Landscape
Company Profiles
Related Reports

Download Detailed TOC @ https://databridgemarketresearch.com/toc/?dbmr=global-atopic-dermatitis-market

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Atopic Dermatitis Market Size to 2026: Velite Pharmaceuticals, Galderma SA, Pfizer Inc, Fujisawa Healthcare, Inc., Dow, Regeneron Pharmaceuticals, Inc here

News-ID: 2145065 • Views:

More Releases from Data Bridge Market Research

Water Treatment System Market: Sustaining the Future of Clean Water
Water Treatment System Market: Sustaining the Future of Clean Water
Introduction Understanding Water Treatment Systems Water treatment systems are designed to purify and disinfect water for various uses-drinking, industrial processes, irrigation, and wastewater reuse. These systems eliminate contaminants such as bacteria, viruses, heavy metals, chemicals, and particulates, making water safe and sustainable for consumption and use. Importance in Global Sustainability Clean water is essential to life and industrial progress. With growing water demand and pollution, water treatment systems are now critical infrastructure across the
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032. With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032. With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032. With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal

All 5 Releases


More Releases for Atopic

Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations. How Large Will the Atopic Dermatitis Market Size By 2025? The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Atopic Dermatitis Pipeline
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029. Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”. In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to